On December 1, 2025, Xeris Biopharma Holdings, Inc. announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for their XP-8121 patent application. This is a significant event for the company, reflecting positive sentiment as it may enhance their product portfolio.